ГАСТРОИНТЕСТИНАЛЬНЫЕ ПРОБЛЕМЫ, СВЯЗАННЫЕ С ШИРОКИМ ПРИМЕНЕНИЕМ НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ У ДЕТЕЙ
https://doi.org/10.15690/vsp.v13i5.1155
Аннотация
В статье рассмотрены механизмы действия, разнообразные эффекты нестероидных противовоспалительных препаратов, согласованная точка зрения на риски развития индуцированного ими поражения верхнего и нижнего отдела желудочно-кишечного тракта, а также пути их преодоления. Охарактеризованы препараты с относительно небольшим побочным влиянием на желудочно-кишечный тракт.
Ключевые слова
дети,
нестероидные противовоспалительные препараты,
осложнения,
гастроинтестинальная токсичность,
дериваты пропионовой кислоты
При поддержке: «Рекитт Бенкизер»
Об авторе
Н. И. Урсова
Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского
Россия
Урсова Наталия Игоревна, доктор медицинских наук, профессор, руководитель педиатрического отделения МОНИКИ им. М.Ф. Владимирского, профессор кафедры педиатрии ФУВ МОНИКИ, главный педиатр Министерства здравоохранения Московской области
Россия
Урсова Наталия Игоревна, доктор медицинских наук, профессор, руководитель педиатрического отделения МОНИКИ им. М.Ф. Владимирского, профессор кафедры педиатрии ФУВ МОНИКИ, главный педиатр Министерства здравоохранения Московской области
Список литературы
1. Case J. P., Baliunas A. J., Block J. A. Lack of efficacy of aceta minophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with didofenac sodium. Arch. Intern. Med. 2003; 163: 169–178.
2. Singh G., Ramey D. R. NSAID induced gastrointestinal complications: the ARAMIS perspective. J. Rheumatol. 1998; 25: 8–16.
3. Cryer B. NSAID-associated death: the rise and fall of NSAID-associated Gl mortality. Am. J. Gastroenterol. 2005; 100: 1694–1695.
4. Fries J. F., Murtagh K. N., Bennett M. The rise and decline of nonsteroidal drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum. 2004; 50: 2433–2440.
5. Maiden L., Thjodleifsson B., Seigal A., Bjarnason II., Scott D., Birgisson S., Bjarnason I. Влияние длительного приема нестероидных противовоспалительных средств и селективных ингибиторов циклооксигеназы-2 на тонкую кишку: поперечное исследование методом капсульной энтероскопии. Пер. с англ. Клиническая гастроэнтерология и гепатология (Русское издание). 2009; 2 (2): 113–119.
6. Stalnikowicz R., Rachmilewitz D. NSAID-induced gastroduodenal damage: is prevention needed? A review and meta-analysis. J. Clin. Gastroenterol. 1993; 17: 238–243.
7. Smalley W. E., Griffin M. R. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol. Clin. North Am. 1996; 25: 373–396.
8. Fries J. F. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J. Rheumatol. Suppl. 1991; 28: 6–10.
9. Bollini P., Rodriguez G., Gutthann S. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch. Intern. Med. 1992; 152: 1289–1295.
10. MacDonald T., Morant S., Robinson G. Association of upper gastro intestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort Study. BMJ. 1997; 315: 1333–1337.
11. Armstrong C., Blower A. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 1987; 28: 527–532.
12. Gabriel S. E., Jaakkimainen L., Bombardier С. Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs. Ann. Intern. Med. 1991; 115: 787–796.
13. Singh G., Ramey D. R. NSAID induced gastrointestinal complications: the ARAMIS perspective. J. Rheumatol. 1998; 25: 8–16.
14. Lanas A., Perez-Aisa M. A., Feu F. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with non-steroidal anti-inflammatory drug use. Am. J. Gastroenterol. 2005; 100: 1685–1693.
15. Singh D., Triadafilopoulos S. Appropriative choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int. J. Clinic. Pract. 2005; 59: 1210–1215.
16. Rostom A., Moayyedi P., Hunt R. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment. Pharmacol. Ther. 2009; 29 (5): 481–496.
17. Venerino M., Malfertheiner P. Interaction of Helicobacter pylori infection and Nonsteroidal Anti-inflammatory Drugs in Gastric and Duodenal ulcers. Helicobacter. 2010; 15: 239–250.
18. Garcia Rodriguez L. A., Hernandez-Diaz S. Relative risk of upper gastro intestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001; 12: 570–576.
19. Laporte J., Ibanez L., Vidal X., Vendrell L., Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 2004; 27: 411–420.
20. Lanas A., Garcia-Tell G., Armada B., Oteo-Alvaro A. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Medicine. 2011; 9: 38. Doi: 10.1186/1741-7015-9-38.
21. Chan F. K., Abraham N. S., Scheiman J. M., Laine L. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular effects of nonsteroidal antiinflammatory drugs and anti-platelet agents. Am. J. Gastroenterol. 2008; 103: 2908–2918.
22. Клиническая фармакология по Гудману и Гилману. Под общей ред. А. Г. Гилмана. Пер. с англ. М.: Практика. 2006. С. 533–557.
23. Han X., Fink M. P., Delude R. L. Proinflammatory cytokines cause NO-dependent and independent changes in expression and localization of tight junction proteins in intestinal epithelial cells. Shock. 2003; 19: 229–237.
24. Marcinkiewicz J., Chain B., Nowak B. Antimicrobal and cytotoxic activity of hypochlorous acid: interactions with taurine and nitrite. Inflamm. Res. 2000; 49: 280–289.
25. Agorreta J., Garayoa M., Montuenga L. M., Zulueta J. J. Effects of acute hypoxia and lipopolysaccharide on nitric oxide synthase-2 expression in acute lung injury. Am. J. Respir. Crit. Care. Med. 2003; 168: 287–296.
26. Guigot G., Guimbaund R. Inducible nitric oxide synthase activity in colon biopsies from inflammatory areas: correlation with inflammation intensity in patients with ulcerative colitis but not with Crohn`s disease. Amino Acids. 2000; 18: 229–235.
27. Grisham M. B., Pavlick K. P., Laroux F. S. Nitric oxide and chronic gut inflammation: conroverde in inflammatory bowel disease. J. Invest. Med. 2002; 50: 272–283.
28. Fons M., Gomez A., Karjalainen T. Mechanisms of colonization and colonization resistance of the digestive tract. Microbial Ecol. Health Dis. Sup. 2000; 2: 240–246.
29. Копанев Ю. А., Соколов А. Л. Дисбактериоз кишечника: микробиологические, иммунологические и клинические аспекты микроэкологических нарушений у детей. М. 2002. 148 с.
30. Hernandez-Diaz S., Rodriguez L. A. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch. Intern. Med. 2000; l (60): 2093–2099.
31. de Abajo F. J., Garcia Rodriguez L. A. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin. Pharmacol. 2001; 1: 1.
32. Simon L.S., Mills J. A. Nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. 1980; 302 (11): 79–1185, 1237–1243.
33. Derry S., Loke Y. K. Risk of gastrointestinal haemorrhage with long term use of ASA: meta-analysis. BMJ. 2000; 321: 1183–1187.
34. MacDonald T. M., Wei L. Effect of ibuprofen on cardioprotective effect of ASA. Lancet. 2003; 361: 573–574.
35. Sung J. J. Management of non-steroidal anti-inflammatory drugrelated peptic ulcer bleeding. Am. J. Med. 2001; 110: 29–32.
36. Jacobsen R. B., Phillips B. B. Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal anti-inflammatory drugs. Ann. Pharmacother. 2004; 38: 1469–1481.
37. Yeomans N. D. A clinical approach to management of patients with non-steroidal anti-inflammatory gastropathy. Ital. J. Gastroenterol. Hepatol. 1999; 31: 89–92.
38. Canadian Coordinating Office for Health Technology Assessment. Gastroduodenal ulcers associated with the use of nonsteroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Ottawa. 2003. Report no. 38. 79 p.
39. Барскова В. Г. Письмо редактора. Современная ревматология. 2011; 2: 82–83.
40. Southey E. R., Soareus-Weiser K., Kieijnen J. Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatrics pain and fever. Curr. Med. Res. Opin. 2009; 25 (9): 2207–2222.
41. Perrott D. A., Piira T., Goodenough B., Champion G. D. Efficacy and safety of acetaminophen vs ibuprofen for treating childrens pain or fever: a meta-analysis. Arch. Pediatr. Adolesc. Med. 2004; 158 (6): 521–526.
42. Pierce C. A., Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann. Pharmacother. 2010; 44 (3): 489–506.
43. Bradbury F. How important is the role of the physician in the correct use of a drug? An observational cohort study in general practice. Int. J. Clin. Pract. 2004; 144: 27–32.
Рецензия
Для цитирования:
Урсова Н.И. ГАСТРОИНТЕСТИНАЛЬНЫЕ ПРОБЛЕМЫ, СВЯЗАННЫЕ С ШИРОКИМ ПРИМЕНЕНИЕМ НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ У ДЕТЕЙ. Вопросы современной педиатрии. 2014;13(5):86-90. https://doi.org/10.15690/vsp.v13i5.1155
For citation:
Ursova N.I. GASTROINTESTINAL PROBLEMS ASSOCIATED WITH THE EXTENSIVE USE OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IN CHILDREN. Current Pediatrics. 2014;13(5):86-90. (In Russ.) https://doi.org/10.15690/vsp.v13i5.1155
Просмотров: 567
Послать статью по эл. почте 
